Short Communication

Clinical research in oncology: in memory of Professor Gordon McVie

13 Jan 2022
Ian F Tannock

Gordon McVie campaigned throughout his career for merging scientific and clinical expertise and for investigating the underlying pharmacokinetics and pharmacodynamics in clinical trials. This need remains highly relevant today when most cancer clinical trials investigate agents that target a known molecular pathway, yet anticancer drug development has changed minimally from that used for chemotherapy when more was better and substantial toxicity inevitable. Here, I summarise some common problems that confound current drug development, including problems in interpreting results of phase 3 randomised trials, as well as trials investigating personalised medicine.

Related Articles

Yumna Ahmed, Agha Muhammad Hammad Khan, Fatima Shaukat, Rabia Tahseen, Maria Tariq, Bilal Mazhar, Sehrish Abrar, Nasir Ali
Nada Benhima, Mohamed El Fadli, Ismail Essâdi, Rhizlane Belbaraka
Sanjit Kumar Agrawal, Himanshu Sharma, Noopur Priya, Anoop P Saji, Hamyung Denchu Phom, Abhishek Sharma, Indu Arun, Jayanta Das, Aditi Chandra, Rosina Ahmed